Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunizations with adenovirus vectors is dependent on haplotype

Journal of Virology

Volumn 71, Issue 3, 1997, Pages 2277-2284

  Sparer, Tim E ^a   Wynn, Susan G ^a   Clark, Daniel J ^a   Kaplan, Johanne M ^b   Cardoza, Lisa M ^b   Wadsworth, Samuel C ^b   Smith, Alan E ^b   Gooding, Linda R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADENOVIRUS; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; GENETIC TRANSCRIPTION; HAPLOTYPE; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0031055469     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.3.2277-2284.1997     Document Type: Article

References (47)

1. Anderson, M., S. Paabo, T. Nilsson, and P. Peterson. 1985. Impaired intracellular transport of class I MHC antigens as a possible means for adenovirus to evade immune surveillance. Cell 43:215-222.
2. Armentano, D., C. C. Sookdeo, K. M. Hehir, R. J. Gregory, J. A. St. George, G. A. Prince, S. C. Wadsworth, and A. E. Smith. 1995. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gen. Ther. 6:1343-1353.
3. Bennink, J. R., J. W. Yewdell, G. L. Smith, and B. Moss. 1986. Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J Virol. 57:786-791.
4. Challberg, S. S., and G. Ketner. 1981. Deletion mutants of adenovirus 2: isolation and initial characterization of virus carrying mutations near the right end of the viral genome. Virology 114:196-209.
5. - antigen P91A by transfected subgenic fragments. Immunogenetics 35:241-252.
6. Clayman, G. L., A. K. el-Naggar, J. A. Roth, W. W. Zhang, H. Goepfert, D. L. Taylor, and T. J. Liu. 1995. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 55:1-6.
7. Cox, J. H., J. W. Yewdell, L. C. Eisenlohr, P. R. Johnson, and J. R. Bennink. 1990. Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science 247:715-8.
8. Doherty, P., W. Allan, and M. Eichelberger. 1992. Roles of αβ and γδ T cell subsets in viral immunity. Annu. Rev. Immunol. 10:123-151.
9. Duerksen-Hughes, P., W. S. Wold, and L. R. Gooding. 1989. Adenovirus E1A renders infected cells sensitive to cytolysis by tumor necrosis factor. J. Immunol. 143:4193-4200.
10. Engelhardt, J. F., L. Litzky, and J. M. Wilson. 1994. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. Gene Ther. 5:1217-1229.
11. Engelhardt, J. F., X. Ye, B. Doranz, and J. M. Wilson. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91:6195-6200.
12. Gooding, L. R. 1980. Anomalous behavior of H-2Kb in immunity to syngeneic SV40 transformed cells: evidence for cytotoxic T cell recognition of H-2/SV40 membrane antigen complexes. J. Immunol. 124:1612-1619.
13. Gooding, L. R. 1977. Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells. J. Immunol. 118:920-927.
14. Gooding, L. R. 1979. Specificities of killing by T lymphocytes generated against syngeneic SV40 transformants: studies employing recombinants within the H-2 complex. J. Immunol. 122:1002-1008.
15. Gooding, L. R., L. W. Elmore, A. E. Tollefson, H. A. Brady, and W. S. Wold. 1988. A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 53:341-346.
16. Green, M., and W. S. Wold. 1979. Human adenoviruses: growth, purification, and transfection assay. Methods Enzymol. 58:425-435.
17. Herz, J., and R. D. Gerard. 1993. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. USA 90:2812-2816.
18. Jones, N., and T. Shenk. 1979. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 17: 683-689.
19. Kageyama, S., T. Tsomides, Y. Sykulev, and H. Eisen. 1995. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J. Immunol. 154:567-576.
20. Kaplan, J. M., D. Armentano, T. E. Sparer, S. G. Wynn, P. A. Peterson, S. C. Wadsworth, K. Couture, S. E. Pennington, J. A. St. George, L. R. Gooding, and A. E. Smith. 1997. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8:45-56.
21. b major histocompatibility complex class I molecule to alloreactive T cells. J. Exp. Med. 182:1739-1750.
22. Moskophidis, D., and R. M. Zinkernagel. 1995. Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. J. Virol. 69: 2187-2193.
23. Mullbacher, A., A. J. Bellett, and R. T. Hla. 1989. The murine cellular immune response to adenovirus type 5. Immunol. Cell. Biol. 67:31-39.
24. Nevins, J. R. 1981. Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 26:213-220.
25. Nowak, M. A., R. M. May, R. E. Phillips, S. Rowland-Jones, D. G. Lalloo, S. McAdam, P. Klenerman, B. Koppe, K. Sigmund, C. R. Bangham, et al. 1995. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 375:606-611.
26. b cytotoxic T lymphocytes. J. Exp. Med. 168:559-570.
27. Fawle, F. C., and L. R. Gooding. Unpublished data.
28. Rawle, F. C., B. B. Knowles, R. P. Ricciardi, V. Brahmacheri, P. Duerksen-Hughes, W. S. Wold, and L. R. Gooding. 1991. Specificity of the mouse cytotoxic T lymphocyte response to adenovirus 5. E1A is immunodominant in H-2b, but not in H-2d or H-2k mice. J. Immunol. 146:3977-3984.
29. Rawle, F. C., K. A. O'Connell, R. W. Geib, B. Roberts, and L. R. Gooding. 1988. Fine mapping of an H-2Kk restricted cytotoxic T lymphocyte epitope in SV40 T antigen by using in-frame deletion mutants and a synthetic peptide. J. Immunol. 141:2734-2739.
30. Rawle, F. C., A. E. Tollefson, W. S. Wold, and L. R. Gooding. 1989. Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K. J. Immunol. 143:2031-2037.
31. Shenk, T. 1996. Adenoviridae: the viruses and their replication. In B. N. Fields (ed.), Virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
32. Sparer, T. E., R. A. Tripp, D. L. Dillehay, T. W. Hermiston, W. S. M. Wold, and L. R. Gooding. 1996. The role of adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. J. Virol. 70:2431-2439.
33. Sykulev, Y., M. Joo, I. Vturina, T. J. Tsomides, and H. N. Eisen. 1996. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4:565-571.
34. Takahashi, H., J. Cohen, A. Hosmalin, K. B. Cease, R. Houghten, J. L. Cornette, C. DeLisi, B. Moss, R. N. Germain, and J. A. Berzofsky. 1988. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 85:3105-3109.
35. bm mutants. J. Virol. 64:1192-2000.
36. Thimmappaya, B., C. Weinberger, R. J. Schneider, and T. Shenk. 1982 Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell 31:543-551.
37. Townsend, A., and H. Bodmer. 1989. Antigen recognition by class I-restricted T lymphocytes. Annu. Rev. Immunol. 7:601-624.
38. Tripp, R. A., and L. R. Gooding. Unpublished data.
39. Welsh, M. J., J. Zabner, S. M. Graham, A. E. Smith, R. Moscicki, and S. Wadsworth. 1995. Adenovirus-mediated gene transfer for cystic fibrosis. Part A. Safety of dose and repeat administration in the nasal epithelium. Part B. Clinical efficacy in the maxillary sinus. Hum. Gene Ther. 6:205-218.
40. Yang, Y., H. C. Ertl, and J. M. Wilson. 1994. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1:433-442.
41. Yang, Y., Q. Li, H. C. Ertl, and J. M. Wilson. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:2004-2015.
42. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gonczol, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407-4411.
43. Yang, Y., F. A. Nunes, K. Berencsi, E. Gonczol, J. F. Engelhardt, and J. M. Wilson. 1994. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7:362-369.
44. + CTLs in vivo. J. Immunol. 155:2564-2570.
45. Zabner, J., L. A. Couture, R. J. Gregory, S. M. Graham, A. E. Smith, and M. J. Welsh. 1993. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75:207-216.
46. Zabner, J., D. M. Petersen, A. P. Puga, S. M. Graham, L. A. Couture, L. D. Keyes, M. J. Lukason, J. A. St George, R. J. Gregory, A. E. Smith, et al. 1994. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat. Genet. 6:75-83.
47. Zhang, X. L., A. J. Bellett, R. T. Hla, A. W. Braithwaite, and A. Mullbacher. 1991. Adenovirus type 5 E3 gene products interfere with the expression of the cytolytic T cell immunodominant E1a antigen. Virology 180:199-206.